ACADIA Pharmaceuticals Inc. Profile Avatar - Palmy Investing

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the tr…
Biotechnology
US, San Diego [HQ]

Ratios

15 Sheets · Starting from 2023
Margins, Growth Rates In %
Ratio 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
100.00 100.00 100.00 100.00 100.00 100.00 100.00 74.58 89.54 91.81 94.22 95.35 96.05 98.03 93.70
Profit Margin
-705.50 35.93 -1,101.35 -424.88 -3,314.24 -77,062.50 -269,578.69 -1,565.94 -231.71 -109.56 -69.38 -63.74 -34.67 -41.76 -8.44
Operating Margin
-710.55 35.82 -1,105.56 -425.64 -3,344.72 -77,691.67 -269,855.74 -1,574.14 -234.11 -110.56 -72.71 -64.87 -35.20 -43.23 -10.10
EPS Growth
30.64 132.50 -212.82 13.64 -15.79 -115.91 -71.58 -43.56 -0.86 17.80 17.53 -11.88 41.34 -27.62 72.39
Return on Assets (ROA)
-90.87 39.43 -70.89 -19.20 -20.07 -28.41 -74.11 -48.36 -75.27 -45.39 -30.04 -35.98 -23.98 -36.74 -8.18
Return on Equity (ROE)
-372.67 50.99 -97.44 -24.53 -20.84 -29.88 -82.32 -52.35 -86.32 -51.18 -33.65 -44.91 -31.04 -53.94 -14.19
Return on Invested Capital (ROIC)
-361.52 50.65 -97.68 -24.45 -21.03 -30.06 -82.57 -52.89 -87.55 -51.92 -34.91 -42.45 -28.22 -48.93 -18.02
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
0.93 0.29 0.10 - - - - - - - - - - - - - - 1.25 6.33 9.20 10.55 7.64
Debt/Equity
3.82 0.37 0.14 - - - - - - - - - - - - - - 1.40 7.90 11.91 15.48 13.25
Debt/EBITDA
39.81 -42.92 30.39 277.21 30.63 66.35 62.05 59.98 23.74 54.46 74.36 98.25 53.57 23.64 193.81
Debt/Capitalization
3.68 0.37 0.14 - - - - - - - - - - - - - - 1.38 7.32 10.64 13.41 11.70
Interest Debt per Share USD
0.01 - - - - - - - - - - - - - - - - - - 0.07 0.31 0.40 0.42 0.35
Debt Growth
-62.20 -76.24 -70.91 -100.00 - - - - - - - - - - - - - - 598.95 26.24 10.47 -7.73
Liquidity
Current Ratio
329.59 635.16 518.23 1,824.95 2,698.95 2,050.13 999.86 1,286.60 761.73 883.25 1,016.02 677.21 643.11 404.31 242.33
Quick Ratio
319.98 622.37 503.62 1,815.18 2,662.13 2,042.76 989.73 1,259.07 733.78 841.62 982.68 643.82 610.04 382.00 212.86
Cash Ratio
123.22 114.94 111.74 973.42 167.75 390.64 466.34 384.22 141.58 226.24 253.49 307.67 153.47 91.42 74.20
Operating Cash Flow Ratio
- - -100 -300 -300 -400 -400 -500 -400 -400 -200 -200 -100 -100 - - - -
Turnover
Inventory Turnover
- - - - - - - - - - - - - - 105.53 248.86 450.37 309.07 212.25 242.88 153.20 127.67
Receivables Turnover
- - - - - - - - - - 12.45 3.72 242.73 677.71 805.38 895.27 878.56 740.92 819.97 709.76
Payables Turnover
- - - - - - - - - - - - - - 112.63 148.65 578.78 271.37 241.96 278.37 79.76 260.68
Asset Turnover
12.88 109.74 6.44 4.52 0.61 0.04 0.03 3.09 32.48 41.43 43.29 56.45 69.15 87.99 96.99
Coverage
Interest Coverage
-52,869.77 -40,794.59 - - - - - - - - - - - - - - - - - - - - - - -3,382.69 - -
Asset Coverage
7,600 29,500 81,100 - - - - - - - - - - - - - - 11,100 1,500 1,000 700 700
Cash Flow Coverage (CFGR)
-2,964.79 -9,730.00 -62,178.13 - - - - - - - - - - - - - - -1,542.93 -274.82 -195.03 -183.93 29.20
EBITDA Coverage
-51,500 -42,400 - - - - - - - - - - - - - - - - - - - - - - -3,300 - -
Dividend Coverage
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Time Interest Earned (TIE)
- - 100 - - - - - - - - - - - - - - - - - - - - - - - - - -
Market Prospects
Dividend Yield
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Earnings Yield
-91.26 32.69 -40.39 -8.17 -1.77 -3.00 -4.58 -8.12 -7.84 -11.98 -3.74 -3.35 -4.48 -8.39 -1.20
Price/Earnings (P/E)
-109.58 305.91 -247.56 -1,223.68 -5,644.61 -3,338.87 -2,181.58 -1,231.18 -1,275.55 -834.79 -2,676.70 -2,987.00 -2,231.43 -1,191.80 -8,369.24
Price/Book (P/B)
408.36 155.99 241.24 300.20 1,176.09 997.65 1,795.87 644.54 1,101.00 427.25 900.71 1,341.43 692.54 642.83 1,187.98
Price/Sales (P/S)
773.06 109.91 2,726.54 5,199.22 187,075.79 2,573,020.00 5,881,081.15 19,279.58 2,955.53 914.56 1,857.16 1,903.98 773.72 497.64 706.07
Price/Cash Flow (P/CF)
-360.37 -432.70 -283.25 -1,179.34 -6,742.48 -4,647.66 -2,945.49 -1,588.03 -1,694.45 -1,222.22 -4,166.73 -6,176.96 -2,980.99 -2,257.20 30,709.93
End of ACAD's Analysis
CIK: 1070494 CUSIP: 004225108 ISIN: US0042251084 LEI: - UEI: -
Secondary Listings
ACAD has no secondary listings inside our databases.